What stage does Forbion invest at?

Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is Forbion located?

Forbion is headquartered in Naarden, NL.

Does Forbion lead rounds?

Forbion has led 4 of the 8 rounds where its role is on record.

Who does Forbion co-invest with?

Forbion most often shares deals with BioMedPartners, DeepTech & Climate Fonds, Entrepreneur First, among 11 tracked co-investors.

Forbion

Venture capitaloperating company · company profile

Naarden · Pre-Seed–Late Stage · 23 people tracked

Also known as FCPM III SERVICES B.V. · FORBION NORTH AMERICA LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Forbion invests in groundbreaking biotech and other sustainable solutions that improve the health of people and the planet, structured around human health and planetary health themes. The firm integrates ESG principles into its investments, emphasizing patient impact, societal benefits, and sustainability. It manages a family of funds spanning venture, growth, and bioeconomy strategies, backing companies working on rare disease therapies, novel treatments, and sustainable technologies such as plant-based metal extraction.

Invests inAgTech Biotech Cleantech Climate Tech Healthtech Impact & Social Good Medical Devices Amsterdam Europe Germany Global Netherlands North America United States

Source: firm website, verified Aug 25, 2026.

Stage

Pre-Seed–Late Stage

Naarden, MA, NL

Instruments

Equity

Founded

1999

Last 12 months

3 investments

AUM

$5.4B

VC funds

Tracked investments

Team · 23 people

from the firm's website & public directories

Geert-Jan Mulder· Co-founding Managing Partner· Naarden, Netherlandsin

Geert-Jan Mulder is a co-founding Managing Partner at Forbion who has led investments across Europe and the US and works with portfolio company management teams on clinical development strategy and regulatory matters such as IND/NDA filings and orphan designations. Before Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences from 2001, and earlier held roles in the pharmaceutical industry at Byk Gulden (now Takeda) as Clinical Research Manager and at Searle (now Pfizer) as Medical Adviser. He holds a Medical Degree from the University of Utrecht and completed two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht.

Martien van Osch· Managing Partner, CFO and co-founder· Boston, MAin 𝕏

Martien van Osch is Managing Partner, CFO and co-founder of Forbion, where he leads the firm's US office in Boston and sits on the Ventures and Growth investment committee. He represented Forbion in Asia from Singapore between 2018 and 2023 and previously led the firm's Fund I-III medical technology investments. Before co-founding Forbion in 2006, he spent six years as an Investment Director at ABN AMRO Capital Life Sciences and holds a degree in Econometrics from the Rijksuniversiteit Groningen.

Alexander Hoffmann· General Partner· Amsterdam Areain

Alexander Hoffmann is a General Partner at Forbion, where he set up and co-led the BioEconomy strategy. He previously was Managing Director at a family office joint-venture focused on early-stage bio-based climate startups, and began his venture career at M Ventures, the venture arm of Merck KGaA, covering Frontier Tech & Sustainability investments spanning digital healthcare and biotech. Earlier, he worked as an operator in tech startups and led Merck's digital strategy for its Africa operations from Nairobi, Kenya.

Dirk Kersten· Managing Partner· Amsterdam, Netherlandsin

Dirk Kersten is a Managing Partner at Forbion, which he joined in 2018, where he manages the Forbion Growth Opportunities Fund. Trained as a physicist, he previously served as a Partner at Gilde Healthcare Partners, leading its Boston office, and as a Managing Director at INKEF Capital overseeing healthcare investments. His work spans fund management, deal making, portfolio management, and exit strategies.

Dmitrij Hristodorov· General Partner· Munich, Germanyin

Dmitrij Hristodorov is a General Partner at Forbion, where his portfolio spans multiple stages, treatment modalities, and disease areas. He previously held R&D Ophthalmology and Business Development roles at Bayer Pharma. He earned a PhD from the University of Aachen (RWTH) in 2013 for immunology work conducted at the Fraunhofer Institute.

Jasper Bos· General Partner· Naarden, Netherlandsin

Jasper Bos is a General Partner at Forbion's Growth Fund. He previously served as Senior Vice President and Managing Director at M Ventures, Merck's venture arm, which he joined in 2009, where he led a team of investment professionals managing a €400 million fund across more than 50 biotech, life sciences tools, and tech companies. He holds a PhD in Pharmacy from the University of Groningen.

Jon Edwards· General Partner· Bostonin

Jon Edwards is a General Partner at Forbion who works on sourcing, evaluating, and structuring investments spanning company creation through early clinical development across therapeutic areas. He joined Forbion in 2025 and was previously a founding team member at Red Tree Venture Capital and Medicxi, with earlier roles at ClearView Healthcare Partners and Sepracor. He completed postdoctoral research at MIT and holds a PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

Joy Faucher· General Partner· Netherlandsin

Joy Faucher is a General Partner at Forbion, which he joined in 2023 to establish and co-lead the firm's BioEconomy strategy. He previously invested in growth and early-stage companies at Lightrock and MVentures (Merck's corporate venture arm), and held operational roles at Formo and Eli Lilly's biotech commercial launch facility. He holds a Master's in Bioscience Enterprise from the University of Cambridge and a Bachelor's in Biochemical Engineering from University College London.

Marco Boorsma· General Partner· Amsterdam, Netherlandsin

Marco Boorsma is a General Partner at Forbion, which he joined in 2007. Before Forbion, he was Business Development Director at DSM Pharmaceutical Products and worked on manufacturing processes for biosimilars at Cytos Biotechnology. He focuses on biotechnology, operations, and business development, with an emphasis on founding and managing new companies as part of Forbion's build strategy, and holds an MSc in Molecular Biology from the University of Groningen and a PhD in Biotechnology from ETH Zürich.

Nanna Lüneborg· General Partner

General Partner at Forbion, holds a PhD and MBA.

Robbert van de Griendt· General Partner· The Netherlandsin

Robbert leads fundraising and investor relations at BGV and heads Forbion's ESG and impact investing efforts. He previously founded Accretion Capital Partners and was a partner at Virage Capital and Neotech Capital, with over 20 years of experience across Asia, Europe, and North America, and holds a Business Economics degree from Erasmus University Rotterdam.

r•••@biogeneration.vcreveal

Rogier Rooswinkel· General Partner· Naardenin

Rogier Rooswinkel is a General Partner at Forbion's Naarden office, which he joined in 2013, where he evaluates and structures new investment opportunities across disease areas with a focus on oncology. Before Forbion, he was a post-doctoral researcher at the Netherlands Cancer Institute (NKI) in the division of immunology, and during his studies he worked as an independent website designer and founded an IT company. He earned a PhD Cum Laude from the University of Amsterdam in 2013 for work at the NKI, and holds a Master's degree in Oncology from VU University Amsterdam.

Sander Slootweg· Managing Partner· Netherlandsin

Sander Slootweg is Managing Partner at Forbion, which he co-founded in 2006 after co-founding ABN AMRO Capital/Life Sciences in 2000. His earlier roles at ABN AMRO Bank included buy-out and growth equity investing, equity capital markets syndications, and financial institutions relationship management for Latin America. He holds degrees in Business and Financial Economics from the Free University of Amsterdam and in Business Administration from Nyenrode University, and focuses on life sciences investing.

Wouter Joustra· General Partner· Amsterdam, Netherlandsin

Wouter Joustra is a General Partner at Forbion, which he joined in 2019, where he works on deal origination, portfolio management, and divestment strategies with a focus on the firm's Growth Opportunities Funds targeting late-stage life sciences companies. He previously served as a Senior Trader and Executive Board member of the life sciences franchise at the investment bank Kempen. He holds an M.Sc. in Business Administration and a B.Sc. in International Business and Management, both from the University of Groningen.

Holger Reithinger· General Partner· Munich, Germanyin 𝕏

Nanna Luneborg· General Partner· Denmarkin

Antoine Boulanger Piette· Principal· Amsterdam, Netherlands

Audrey Cacaly· Principal· Netherlandsin

Philip Astley-Sparke· Venture Partner· Boston, Massachusettsin

Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.

Carlo Incerti· Operating Partnerin

Machteld Groeneveld· Legal Counsel and Compliance Officer· Amsterdam, North Holland, Netherlandsin

Machteld Groeneveld joined Forbion in June 2020 and is responsible for Legal, Risk and Compliance. She serves on the board of the Manager of the Forbion funds as Secretary, and is a member of the firm's Valuation Committee and Responsible Investing Committee. Before Forbion she held legal and strategic roles at multinational and publicly listed companies, focusing on European legal affairs, fund compliance, corporate strategy, and value creation through M&A. She holds an LLM from the University of Utrecht, a postgraduate degree in International Contracting from Grotius Academy, and an Executive MBA from RSM Erasmus University.

Alice Vickers· Advisor· United Kingdomin 𝕏

Marc-Olivier Turgeon· Senior Associate· Amsterdam, Netherlandsin

What they invest in

from 31 of 33 portfolio companies

Biotech ×29Healthtech ×13Medical Devices ×13Deep Tech ×5AI & Machine Learning ×4Digital Health ×3SaaS ×2Cleantech ×1

HQs:United States×12United Kingdom×3Netherlands×2Switzerland×1Colombia×1Germany×1

Investments · 33 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 3 2024 · 4 2023 · 1 2021 · 1 2020 · 1 2017 · 1 2015 · 1 2012 · 115 dated

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020SEC filingmedium confidence

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)

BoardLawrence Klein, Ph.D.(Director)

Board seatDirk Kersten· per SEC Form D · $115.7M raise · filed Aug 2020

Co-investorsAtlas Venture MPM BioImpact Vida Ventures Hercules Capital, Inc.

MapLight TherapeuticsNASDAQ: MPLTJul 2025SEC filingmedium confidence

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)James Lillie(Executive Officer)Christopher A Kroeger(Executive Officer, Director)Jonathan Gillis(Executive Officer)

Board seatNanna Luneborg· per SEC Form D · $372.4M raise · filed Jul 2025

Elevaraelevara.com in✓ verified

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)

Co-investorsMonograph Capital Partners Sofinnova Partners

Engrail Therapeuticsengrail.com in✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite Capital Longwood Fund Norwest Venture Partners RiverVest Venture Partners Ysios Capital abrdn plc +4 more

Expeditiontxexpeditiontx.com in✓ verified

Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD).

BiotechHealthtechSan Francisco, US

Co-investorsNovo Holdings Sofinnova Ventures Sanofi Ventures

Gate Biogatebio.com✓ verified

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsVersant Ventures Andreessen Horowitz ARCH Venture Partners GV (Google Ventures)

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)

Co-investorsNovartis Venture Fund Sanofi Ventures Versant Ventures

Kynexiskynexistx.com in 𝕏✓ verified

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)Kees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios Capital Novartis Venture Fund Sunstone Capital

Mestag Therapeuticsmestagtx.com in 𝕏✓ verified

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

Susan Hill(Founder & Chief Executive Officer)Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsGV (Google Ventures)Johnson & Johnson Innovation – JJDC Northpond Ventures SV Health Investors

Omeicos Therapeuticsomeicos.com in 𝕏✓ verified

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)Karen Uhlmann(Vice President Operations & IP, Co-Founder)Wolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRemiges Ventures, Inc.Vesalius Biocapital Partners

Pheontxpheontx.com in✓ verified

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Biotechnology Value Fund Lightspeed Venture Partners Research Corporation Technologies TCG Crossover

Exosome DiagnosticsJun 2015SEC filingmedium confidence

BiotechHealthtechCambridge, US

William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Dhingra Kapil(Director)Sara Barrington(Executive Officer)James McCullough(Executive Officer, Director)

BoardJoseph Boystak(Director)

Board seatGeert-Jan Mulder· per SEC Form D · $2.2M raise · filed Jul 2015

Gyroscope Therapeutics LtdMar 2021SEC filingmedium confidence

Stevenage, Hertfordshire

Board seatWouter Joustra· per SEC Form D · $148M raise · filed Apr 2021

Co-investorsSofinnova Ventures

Memento MedicinesJun 2026

Privately-held biotech company developing biologic therapies for retinal diseases

BiotechBoston, US

William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)

BoardZach Scheiner(Director)inMegan Krench(Director)

Board seatDmitrij Hristodorov· per SEC Form D

Co-investorsSanofi Ventures Avego BioScience Capital RA Capital Samsara BioCapital

Milestone Pharmaceuticalsmilestonepharma.com in 𝕏Jul 2017SEC filingmedium confidence

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Board seatMarco Boorsma· per SEC Form D · $6.9M raise · filed Jul 2017

Co-investorsPappas Capital

Navigator MedicinesAug 2024SEC filingmedium confidence

BiotechScotch Plains, US

NAVEEN MANU DARYANI(Executive Officer)STEPHEN BASIL THOMAS(Executive Officer, Director, Promoter)WILLIAM DALEY BONIFICIO(Executive Officer, Promoter)

BoardANDREW LEVIN(Director)

Board seatWouter Joustra· per SEC Form D · $100M raise · filed Sep 2024

Co-investorsRA Capital

Amphistaamphista.com in 𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)

Co-investorsAdvent Life Sciences Novartis Venture Fund SV Health Investors Dementia Discovery Fund European Investment Fund Gilde Healthcare +1 more

Azafarosazafaros.com

Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism.

BiotechMedical Devices

Co-investorsBioMedPartners Jeito Capital Seroba Life Sciences BioGeneration Ventures

Citryllcitryll.com in

Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.

BiotechHealthtechMedical DevicesOss, NL

Co-investorsBOM Curie Capital Novartis Venture Fund Pureos Bioventures BioGeneration Ventures

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)

Co-investorsLongwood Fund Sofinnova Ventures BAM Elevate Finchley Healthcare Ventures Luma Group Novo Holdings +1 more

F2Gf2g.com

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.

BiotechHealthtech

Co-investorsAdvent Life Sciences Aisling Capital AMR Action Fund Astellas Venture Management LLC Brace Pharma Sofinnova Partners +3 more

Forbionforbion.com

Forbion is a global venture capital firm that invests in biotech innovations and sustainable solutions focused on human and planetary health.

BiotechClimate TechImpact & Social Good

Co-investorsBOM KfW Capital

Genominesgenomines.com in

Genomines uses biological systems to extract battery-grade nickel from low-grade soils, producing critical metals at lower cost and environmental impact than traditional mining.

BiotechCleantechEnergyNew MaterialsParis, FR

Fabien Koutchekian(CEO)inDali Rashid(CTO)in

Co-investorsCarbon DeepTech & Climate Fonds Entrepreneur First LOWERCARBON Lowercarbon Capital STATION F +4 more

LoQus23loqus23.com inOct 2024

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsNovartis Venture Fund SV Health Investors Dementia Discovery Fund

Mariana Oncologymarianaoncology.com in 𝕏Sep 2023 · $175M

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess Biotechnology Atlas Venture Nextech Invest RA Capital

Noema Pharmanoemapharma.com inNov 2025

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)

Co-investorsBioMedPartners Jeito Capital Roche Venture Fund Sofinnova Partners EQT EQT Life Sciences +2 more

Progentos Therapeuticsprogentos.comMay 2024 · $65M

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.

BiotechDeep TechMedical DevicesWatertown, US

Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)

BoardAleks Radovic-Moreno(Director)inDan Janney(Director)

Co-investorsAlta Partners Longwood Fund Mission Biocapital Dolby Family Ventures Service Provider Capital

Promediorpromedior.comFeb 2012

BiotechMalvern, US

Mark Lupher(Executive Officer)James W. Broderick, M.D.(Director)Dominick C. Colangelo(Executive Officer, Director)Paul D. Goldenheim, M.D.(Director)Harold R. Werner(Director)Amir Nashat(Director)

Co-investorsEaston Capital Sofinnova Ventures Easton Capital Investment Group

Protegoprotegosolutions.io 𝕏Defunct

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

Pablo Rojas(Founder)in

Co-investorsNovartis Venture Fund Y Combinator Glilot Capital Partners Omega Funds YK Bioventures

Protegoprotegobio.com

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US

Co-investorsDroia Ventures Novartis Venture Fund Digitalis Ventures Lightspeed Venture Partners MPM BioImpact Vida Ventures +1 more

Purespringpurespringtx.com in 𝕏Oct 2024

Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.

BiotechHealthtechMedical Devices

Co-investorsSofinnova Partners British Patient Capital Gilde Healthcare

Tropictropicapp.io in

Tropic is a procurement platform that gives finance and procurement teams pricing intelligence, negotiation playbooks, and expert support to reduce spend on SaaS and AI software.

AI & Machine LearningFintechSaaSNew York City, US

Justin Etkin(Founder)David Campbell(Founder)in

Co-investorsShine Capital

VectorY

A fully integrated gene therapy company developing innovative therapeutics including vectorized antibodies for CNS and somatic disorders, with focus on muscle diseases.

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 2

IPOs and acquisitions across the tracked portfolio

Dyne TherapeuticsNASDAQ: DYNMapLight TherapeuticsNASDAQ: MPLT

Portfolio news

latest coverage across their companies

Finance Watch: Venture Capital Investors Meet Biotechs In The Middle

Kynexis · insights.citeline.com · Aug 20, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Forbion · fiercebiotech.com · Aug 12, 2026

Intellectia

Dyne Therapeutics · intellectia.ai · Jul 1, 2026

Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease | Ophthalmology Times - Clinical Insights for Eye Specialists

Memento Medicines · ophthalmologytimes.com · Jun 24, 2026

Coultreon Biopharma secures $125M to advance SIK3 drug

Coultreon · bioxconomy.com · Apr 29, 2026

Rilian Raises $17.5M in Seed Funding

Protego · finsmes.com · Apr 23, 2026

Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026 - BioSpace

Navigator Medicines · biospace.com · Mar 30, 2026

Tropic raises $105M to scale gene-edited bananas

Tropic · thenextweb.com · Mar 13, 2026

Fund performance · per public LP disclosures · 5

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Forbion BioEconomy Fund I Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.90x	0.00x
Forbion Growth Opportunities Fund III Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.65x	0.07x
Forbion Ventures Fund VII Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.85x	0.01x
Forbion Growth Opportunities Fund II Cooperatief U.A.LPs: California Public Employees' Retirement System	2023	—	—	1.64x	1.01x
Forbion Ventures Fund VI Cooperatief U.A.LPs: California Public Employees' Retirement System	2023	—	—	1.34x	0.34x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does Forbion invest at?: Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Forbion focus on?: Forbion focuses on AgTech, Biotech, Cleantech, Climate Tech, Healthtech, Impact & Social Good, Medical Devices.
Where is Forbion located?: Forbion is headquartered in Naarden, NL.
Does Forbion lead rounds?: Forbion has led 4 of the 8 rounds where its role is on record.
Who does Forbion co-invest with?: Forbion most often shares deals with BioMedPartners, DeepTech & Climate Fonds, Entrepreneur First, among 11 tracked co-investors.

Media · Podcasts & interviews

featuring the team

BIO-Europe® 2015: Interview with Sander Slootweg, Forbion Capital Partners

EBD Group · Sander Slootweg

Forbion Portfolio Company Spotlight Series | Episode 1: VectorY

Forbion

Message by Olivér Várhelyi on the occasion of the European Life Sciences Coalition

Forbion

Forbion 2nd Annual Excellence Roundtable: The future of innovation in rare diseases

Forbion

From Bench to Boardroom: The 2nd Annual Cambridge–Forbion Roundtable

Forbion

Forbion Patient Perspective Series | Episode 1 - What ALS can't take from Marcel

Forbion

Images

Co-investors · 41

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.

Both backed · 7

Amphista Citryll F2G Granite Bio Kynexis LoQus23 Protego

$5M – $25M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 4

Elevara F2G Noema Pharma Purespring

$540K – $27M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 4

Coultreon Expeditiontx PromediorGyroscope Therapeutics Ltd

$100K – $15M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 3

Dyne Therapeutics Mariana Oncology Pheontx

$500K – $1M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 3

Mariana Oncology Memento Medicines Navigator Medicines

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 3

Expeditiontx Granite Bio Memento Medicines

$5M

Longwood Fund

Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.

Both backed · 3

Coultreon Engrail Therapeutics Progentos Therapeutics

Versant Ventures

Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.

Both backed · 2

Gate Bio Granite Bio

$250K – $5M

BioGeneration Ventures

BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.

Both backed · 2

Azafaros Citryll

Ysios Capital

Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.

Both backed · 2

Engrail Therapeutics Kynexis

$5.4M – $21.6M

Advent Life Sciences

Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.

Both backed · 2

Amphista F2G

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 1

Engrail Therapeutics

$3M – $10M

▶29 more co-investors

ARCH Venture Partners EQT Life Sciences Pivotal Life Sciences Nextech Invest RiverVest Venture Partners Alta Partners Seroba Life Sciences Red Tree Venture Founders Fund New Enterprise Associates (NEA)Polaris Partners US Venture Partners General Atlantic OrbiMed Xtripe Angels HTGF 5AM Ventures Cambridge Innovation Capital Domain Associates Third Rock Ventures Pfizer Venture Investments Kurma Partners Access Industries Andera Partners Seventure Partners Inkef RTW Investments L.P.4see Ventures Arcus Ventures

Firms observed investing alongside Forbion, from public investor directories. Shared companies are the overlap with Forbion's recorded portfolio.

Similar investors

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Innovestor Ventures

Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.

$270K – $3.2M

MDI Ventures

MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.

$500K – $75M

UntroD Capital

UntroD Capital is a deep-tech-focused investment firm that backs research-and-development-driven startups whose innovative technologies address challenges facing the planet and humanity, an approach it terms 'Real Tech'.

$772K – $241M

Sofinnova Partners

$540K – $27M